The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies

Autoimmunity Reviews

Volumn 13, Issue 1, 2014, Pages 64-69

  Novelli, Lucia ^a   Chimenti, Maria Sole ^a   Chiricozzi, Andrea ^a,b   Perricone, Roberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

IL 17; IL 23; Psoriasis; Psoriatic arthritis; Th17 cells; Therapeutic targets

Indexed keywords

ABT 122; BRIAKINUMAB; BRODALUMAB; CHEMOKINE RECEPTOR CCR6; CXCL1 CHEMOKINE; CXCL3 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; IXEKIZUMAB; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PERAKIZUMAB; PLACEBO; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SCH 900117; SECUKINUMAB; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; USTEKINUMAB;

ANGIOGENESIS; ANKYLOSING SPONDYLITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE UVEITIS; BINDING AFFINITY; BONE REMODELING; CELL INFILTRATION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LYMPHOCYTE PROLIFERATION; MULTICENTER STUDY (TOPIC); NEUTROPENIA; NEUTROPHIL; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN TARGETING; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TH2 CELL; UPPER RESPIRATORY TRACT INFECTION;

IL-17; IL-23; PSORIASIS; PSORIATIC ARTHRITIS; TH17 CELLS; THERAPEUTIC TARGETS;

ANIMALS; ANTIBODIES; ARTHRITIS, PSORIATIC; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 84886951567     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.08.006     Document Type: Review

References (79)

1. Chimenti M.S., Ballanti E., Perricone C., Cipriani P., Giacomelli R., Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev March 2013, 12(5):599-506. [Pii: S1568-9972(12)00260].
2. Frisenda S., Perricone C., Valesini G. Cartilage as a target of autoimmunity: a thin layer. Autoimmun Rev Mar 2013, 12(5):591-598.
3. Kane D., Stafford L., Bresnihan B., FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) Dec 2003, 42(12):1460-1468.
4. van Kuijk A.W., Tak P.P. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep Aug 2011, 13(4):353-359.
5. McGonagle D., Conaghan P.G., Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum Jun 1999, 42(6):1080-1086.
6. Benjamin M., McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol 2009, 649:57-70.
7. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med Jul 30 2009, 361(5):496-509.
8. Conigliaro P., Scrivo R., Valesini G., Perricone R. Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmun Rev Aug 2011, 10(10):577-581.
9. Cai Y., Fleming C., Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol Jul 2012, 9(4):302-309.
10. Telfer N.R., Chalmers R.J., Whale K., Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol Jan 1992, 128(1):39-42.
11. Salvarani C., Macchioni P., Olivieri I., Marchesoni A., Cutolo M., Ferraccioli G., et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol Oct 2001, 28(10):2274-2282.
12. Nickoloff B.J., Qin J.Z., Nestle F.O. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol Oct 2007, 33(1-2):45-56.
13. Chimenti M.S., Perricone C., Graceffa D., Di Muzio G., Ballanti E., Guarino M.D., et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol Jan 2012, 30(1):23-30.
14. Yoo I.S., Lee J.H., Song S.T., Kim J.H., Lee H.J., Kang S.W. T-helper 17 cells: thedriving force of psoriasis and psoriatic arthritis. Int J Rheum Dis Dec 2012, 15(6):531-537.
15. Saraceno R., Bavetta M., Zangrilli A., Chiricozzi A., Potenza C., Chimenti S., Chimenti M.S. Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. Expert Opin Biol Ther Sep 2013, 13(9):1325-1334.
16. Chimenti M.S., Graceffa D., Perricone R. Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission?. Autoimmun Rev Aug 2011, 10(10):636-640.
17. Collamer A.N., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum Dec 2010, 40(3):233-240.
18. Ma H.L., Napierata L., Stedman N., Benoit S., Collins M., Nickerson-Nutter C., et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum Feb 2010, 62(2):430-440.
19. Notley C.A., Inglis J.J., Alzabin S., McCann F.E., McNamee K.E., Williams R.O. Blockade of tumor necrosis factor in collagen induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008, 205:2491-2497.
20. Murphy K.M., Reiner S.L. The lineage decisions of helper T cells. Nat Rev Immunol Dec 2002, 2(12):933-944.
21. Kauffman C.L., Aria N., Toichi E., McCormick T.S., Cooper K.D., Gottlieb A.B., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol Dec 2004, 123(6):1037-1044.
22. Torti D.C., Feldman S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol Dec 2007, 57(6):1059-1068. [Epub 2007 Aug 15].
23. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol Jul 1 2005, 175(1):5-14.
24. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol Nov 2005, 6(11):1123-1132.
25. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol Nov 2005, 6(11):1133-1141.
26. Raychaudhuri S.P. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol Apr 2013, 44(2):183-193.
27. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol Dec 15 1995, 155(12):5483-5486.
28. Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol Jun 2007, 8(6):639-646. [Epub 2007 May 7].
29. Chen Z., Tato C.M., Muul L., Laurence A., O'Shea J.J. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum Sep 2007, 56(9):2936-2946.
30. Evans H.G., Suddason T., Jackson I., Taams L.S., Lord G.M. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci U S A 2007, 104:17034-17039.
31. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
32. Wilson N.J., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
33. van Beelen A.J., et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007, 27:660-669.
34. Manel Nicolas, Unutmaz Derya, Littman Dan R. The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγT. Nat Immunol June 2008, 9(6):641-649. [Author manuscript; available in PMC].
35. Gaffen S.L. An overview of IL-17 function and signaling. Cytokine Sep 2008, 43(3):402-407. [Epub 2008 Aug 12]. 10.1016/j.cyto.2008.07.017.
36. Dong W., Zhu P. Functional niche of inflamed synovium for Th17-cell expansion and activation in rheumatoid arthritis: implication to clinical therapeutics. Autoimmun Rev Oct 2012, 11(12):844-851.
37. Kuestner R.E., Taft D.W., Haran A., Brandt C.S., Brender T., Lum K., et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol Oct 15 2007, 179(8):5462-5473.
38. Hofstetter H.H., Ibrahim S.M., Koczan D., Kruse N., Weishaupt A., Toyka K.V., et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol Oct 2005, 237(2):123-130. [Epub 2005 Dec 28].
39. Fenoglio D., Bernuzzi F., Battaglia F., Parodi A., Kalli F., Negrini S., et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev Dec 2012, 12(2):300-304.
40. Apostolidis S.A., Lieberman L.A., Kis-Toth K., Crispín J.C., Tsokos G.C. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res 2011 Oct, 31(10):769-779. [Epub 2011 Aug 30]. 10.1089/jir.2011.0029.
41. Ambrosi A., Espinosa A., Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol Sep 2012, 42(9):2274-2284.
42. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol Dec 1 2003, 171(11):6173-6177.
43. Bush K.A., Farmer K.M., Walker J.S., Kirkham B.W. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum Mar 2002, 46(3):802-805.
44. Chabaud M., Garnero P., Dayer J.M., Guerne P.A., Fossiez F., Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine Jul 2000, 12(7):1092-1099.
45. Benderdour M., Tardif G., Pelletier J.P., Di Battista J.A., Reboul P., Ranger P., et al. Interleukin 17 (IL-17) induces collagenase-3 production in human osteoarthritic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1beta. J Rheumatol Jun 2002, 29(6):1262-1272.
46. Koshy P.J., Henderson N., Logan C., Life P.F., Cawston T.E., Rowan A.D. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis Aug 2002, 61(8):704-713.
47. Hacquard-Bouder C., Chimente M.S., Giquel B., Donnadieu E., Fert I., Schmitt A., et al. Alteration of antigen-independent immunological synapse formation between dendritic cells and CD4+ T cells, in HLA-B27 trnagenic rat: selective impairement of costimulatory molecules engagement, by mature HLA-B27. Arthritis and Rheumatism May 2007, 56(5):1478-1489.
48. Costello P., Bresnihan B., O'Farrelly C., FitzGerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol May 1999, 26(5):1117.
49. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest May 1999, 103(9):1345-1352.
50. LeibundGut-Landmann S., Gross O., Robinson M.J., Osorio F., Slack E.C., Tsoni S.V., et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol Jun 2007, 8(6):630-638. [Epub 2007 Apr 22].
51. Sherlock J.P., et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+CD3+CD4-CD8-entheseal resident T cells. Nat Med Jul 1 2012, 18(7):1069-1076.
52. Ramonda R., Lo Nigro A., Modesti V., Nalotto L., Musacchio E., Iaccarino L., et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev Oct 2011, 10(12):773-778.
53. Chan J.R., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med Nov 27 2006, 203(12):2577-2587. [Epub 2006 Oct 30].
54. Chiricozzi A., Guttman-Yassky E., Suárez-Fariñas M., Nograles K.E., Tian S., Cardinale I., et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol Mar 2011, 131(3):677-687.
55. Yeilding N., et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci Mar 2011, 1222:30-39.
56. Bartlett B.L., Tyring S.K. Ustekinumab for chronic plaque psoriasis. Lancet May 17 2008, 371(9625):1639-1640.
57. Gandhi M., Alwawi E., Gordon K.B. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg Mar 2010, 29(1):48-52.
58. Reddy M., Davis C., Wong J., Marsters P., Pendley C., Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol May 2007, 247(1):1-11. [Epub 2007 Aug 29].
59. Leonardi C.L., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet May 17 2008, 371(9625):1665-1674.
60. Krueger G.G., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med Feb 8 2007, 356(6):580-592.
61. Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet May 17 2008, 371(9625):1675-1684.
62. Gottlieb A., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet Feb 21 2009, 373(9664):633-640.
63. McInnes I.B., Kavanaugh A. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet Aug 2013, 328(9894):780-789. [Pii: S0140-6736(13)60594-2].
64. Kimball A.B., et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol Feb 2008, 144(2):200-207.
65. Kimball A.B., et al. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol Feb 2011, 64(2):263-274.
66. Papp K.A. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol May 17 2013, [Epub ahead of print]. 10.1111/jdv.12177.
67. Maddur M.S., Kaveri S.V., Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev Oct 2011, 10(12):809-810.
68. Garber K. Psoriasis: from bed to bench and back. Nat Biotechnol Jul 11 2011, 29(7):563-566.
69. Hueber W., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med Oct 6 2010, 2(52):52ra72.
70. Genovese M.C., et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis Jun 2013, 72(6):863-869.
71. Hueber W., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut Dec 2012, 61(12):1693-1700.
72. Papp K.A., et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol Feb 2013, 168(2):412-421.
73. Rich P., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol Feb 2013, 168(2):402-411.
74. Papp K.A., et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol Oct 2012, 132(10):2466-2469.
75. McInnes I.B., et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis Jan 29 2013, [Epub ahead of print].
76. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med Mar 29 2012, 366(13):1190-1199.
77. Genovese M.C., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum Apr 2010, 62(4):929-939.
78. Papp K.A., Leonardi C., Menter A., Ortonne J.P., Krueger J.G., Kricorian G., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med Mar 29 2012, 366(13):1181-1189.
79. Rozenblit M., et al. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther Jan-Feb 2009, 22(1):56-60.